Mini kit d’ARN/ADN viral PureLink™
Invitrogen™

Mini kit d’ARN/ADN viral PureLink™

Le mini kit d’ARN / ADN viral PureLink constitue une méthode rapide et efficace de purification simultanée d’ARN / ADNAfficher plus
Have Questions?
RéférenceQuantité
1228005050 préparations
Référence 12280050
Prix (EUR)
287,65
Online Exclusive
335,00
Économisez 47,35 (14%)
Each
Quantité:
50 préparations
Prix (EUR)
287,65
Online Exclusive
335,00
Économisez 47,35 (14%)
Each
Le mini kit d’ARN / ADN viral PureLink constitue une méthode rapide et efficace de purification simultanée d’ARN / ADN viral à partir de liquides biologiques frais ou congelés exempts de cellules (plasma, sérum, liquide céphalorachidien) et de surnageants de culture cellulaire. Le kit est spécialement conçu pour isoler les acides nucléiques viraux de haute qualité d’une variété de virus ARN et ADN en 45 minutes maximum à l’aide de faibles volumes d’élution qui permettent des analyses sensibles en aval. L’ARN / ADN viral purifié est dépourvu de protéines et de nucléases et est adapté à une utilisation dans les applications en aval qui permettent une détection et un génotypage viraux.

Le mini kit viral PureLink a été utilisé pour purifier l’ADNdb virale à partir d’orthopoxvirus, notamment le virus de la variole des vaches, le virus de la variole, le virus de la variole du singe, le virus de la vaccine et HERV.

Le mini kit d’ARN / ADN viral PureLink offre les avantages suivants :
• Purification rapide et efficace d’acides nucléiques viraux de grande qualité à l’aide d’une centrifugation dans une colonne de centrifugation sans contamination croisée des échantillons
• Spécialement conçu pour purifier l’ARN et l’ADN viral à partir de ≤500 µl d’échantillons exempts de cellules en moins de 45 min
• Faculté d’élution des acides nucléiques viraux dans de faibles volumes d’élution de 10 à 50 µl pour permettre des analyses sensibles en aval

Usage exclusivement réservé à la recherche. Ne pas utiliser pour des procédures de diagnostic.
Spécifications
Type de colonneColonne de centrifugation
Volume d’élution10 to 50 μL
Type de produit finalViral RNA and DNA
À utiliser avec (application)PCR quantitative en temps réel (qPCR), PCR par transcriptase inverse (RT-PCR), transfert Northern
Compatibilité à haut débitNon compatible avec des cadences élevées (manuel)
Quantité50 préparations
Type d’échantillonLiquides exempts de cellules, Liquide céphalorachidien, Échantillons liquides (p. ex. sérum), Plasma, Sérum, Virus, Nasopharyngeal Viral Transfer Medium (NPVTM)
BalanceMini
Conditions d’expéditionTempérature ambiante
Quantité de matériel de démarrage≤500 μL
Heure du test45 min
Rendement5 μg (Binding capacity)
Isolation TechnologyColonne de centrifugation de silice
Unit SizeEach
Contenu et stockage
Le mini kit d’ARN / ADN viral PureLink™ contient suffisamment de réactifs pour 50 réactions.

Contenu du kit :
• 32 ml de tampon de lyse virale (L22)
• 15 ml de tampon de lavage 5X (W5)
• 2 × 1,6 ml de protéinase K (20 mg / ml dans un tampon de stockage)
• 310 µg d’ARN porteur lyophilisé
• 15,5 ml d’eau stérile sans RNase
• 50 colonnes de centrifugation virale avec tubes de prélèvement
• 2 × 50 tubes de lavage (2,0 ml)
• 50 tubes de récupération (1,5 ml)

Stocker tous les composants sauf l’ARN porteur à température ambiante. L’ARN porteur doit être stocké à −20°C.

Foire aux questions (FAQ)

Are additional wash tubes available for the PureLink Viral RNA/DNA kits if I do not want to use the wash columns twice?

Yes, the Cat. No. for 100 wash tubes is 12282-100.

What is the stability of the Proteinase K in the PureLink Viral RNA/DNA kits?

The Proteinase K solution is stable for 1 year when stored at room temperature. For long-term storage (>1 year) or if room temperature is >25 degrees C, store the Proteinase K solution at 4 degrees C.

What is the difference between serum and plasma?

Plasma is the liquid portion of the blood that is separated from the blood cells by centrifugation. One of the characteristics of plasma is that it clots easily, which is important for hemophiliacs needing a transfusion but is a nuisance in most other applications. By agitating the plasma, one can precipitate the clotting factors as a large clot, and the leftover fluid is called serum. In other words, serum plus clotting factors is plasma, and clotted plasma yields serum.

What is the stability of the carrier RNA in the PureLink Viral RNA/DNA kit, both lyophilized and in solution?

The tRNA is stable for over one year. There was no significant difference in qRT-PCR results with tRNA stored for 10 days at ‘20 degrees C or 42 degrees C. The lyophilized tRNA is stable at ‘20 degrees C, room temperature, 37 degrees C, and 45 degrees C for up to 1 month.

Do I need to use the carrier RNA in the PureLink Viral RNA/DNA kit?

The carrier RNA is tRNA and it may not be necessary. We have tested without the tRNA and obtained excellent results. The tRNA provides a substrate for RNases in the sample to protect the viral RNA until the virus is lysed. You may want to scale down the amount of carrier RNA or leave it out. However, you should validate it in your application to make sure you get the same results as when you include it.

Citations et références (8)

Citations et références
Abstract
Surveillance of feral cats for influenza A virus in north central Florida.
Authors:Gordy JT,Jones CA,Rue J,Crawford PC,Levy JK,Stallknecht DE,Tripp RA,Tompkins SM
Journal:Influenza and other respiratory viruses
PubMed ID:22212818
Please cite this paper as: Gordy JT et al. (2012) Surveillance of feral cats for influenza A virus in North Central Florida. Influenza and Other Respiratory Viruses 6(5), 341–347. Background  Transmission of highly pathogenic avian influenza and the recent pandemic H1N1 viruses to domestic cats and other felids creates concern because ... More
Widespread Virus Replication in Alveoli Drives Acute Respiratory Distress Syndrome in Aerosolized H5N1 Influenza Infection of Macaques.
Authors:Wonderlich ER,Swan ZD,Bissel SJ,Hartman AL,Carney JP,O'Malley KJ,Obadan AO,Santos J,Walker R,Sturgeon TJ,Frye LJ Jr,Maiello P,Scanga CA,Bowling JD,Bouwer AL,Duangkhae PA,Wiley CA,Flynn JL,Wang J,Cole KS,Perez DR,Reed DS,Barratt-Boyes SM
Journal:Journal of immunology (Baltimore, Md. : 1950)
PubMed ID:28062701
Human infections with highly pathogenic avian influenza A (H5N1) virus are frequently fatal but the mechanisms of disease remain ill-defined. H5N1 infection is associated with intense production of proinflammatory cytokines, but whether this cytokine storm is the main cause of fatality or is a consequence of extensive virus replication that ... More
Production, concentration and titration of pseudotyped HIV-1-based lentiviral vectors.
Authors:Kutner RH, Zhang XY, Reiser J,
Journal:Nat Protoc
PubMed ID:19300443
'Over the past decade, lentiviral vectors have emerged as powerful tools for transgene delivery. The use of lentiviral vectors has become commonplace and applications in the fields of neuroscience, hematology, developmental biology, stem cell biology and transgenesis are rapidly emerging. Also, lentiviral vectors are at present being explored in the ... More
No association of xenotropic murine leukemia virus-related virus with prostate cancer or chronic fatigue syndrome in Japan.
Authors:Furuta RA, Miyazawa T, Sugiyama T, Kuratsune H, Ikeda Y, Sato E, Misawa N, Nakatomi Y, Sakuma R, Yasui K, Yamaguti K, Hirayama F
Journal:Retrovirology
PubMed ID:21414229
The involvement of xenotropic murine leukemia virus-related virus (XMRV) in prostate cancer (PC) and chronic fatigue syndrome (CFS) is disputed as its reported prevalence ranges from 0% to 25% in PC cases and from 0% to more than 80% in CFS cases. To evaluate the risk of XMRV infection during ... More
The microbial detection array for detection of emerging viruses in clinical samples--a useful panmicrobial diagnostic tool.
Authors:Rosenstierne MW, McLoughlin KS, Olesen ML, Papa A, Gardner SN, Engler O, Plumet S, Mirazimi A, Weidmann M, Niedrig M, Fomsgaard A, Erlandsson L
Journal:
PubMed ID:24963710
Emerging viruses are usually endemic to tropical and sub-tropical regions of the world, but increased global travel, climate change and changes in lifestyle are believed to contribute to the spread of these viruses into new regions. Many of these viruses cause similar disease symptoms as other emerging viruses or common ... More